Oculus Innovative Sciences Microcyn(R) Technology to be Showcased at the Columbia University 10th Annual Innovations in Complex Vascular & Endovascular Interventions in New York City on May 10-11, 2012
PETALUMA, Calif., May 9, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (OCLS), a commercial healthcare company that designs, produces and markets innovative, safe and effective healthcare products in multiple markets, announced the company would be exhibiting its Microcyn®-based products at Columbia University's 10th Annual Innovations in Complex Vascular & Endovascular Interventions in New York City, May 10-11, 2012. The two-day educational conference for clinicians will focus on complex arterial and venous vascular procedures, including management options for non-healing wounds and advances in podiatric wound management.
"The Microcyn® Technology has been successfully used for years in the management of a variety of vascular-related wounds including non-healing varicose vein ulcers and diabetic foot ulcers," said Hoji Alimi, Oculus CEO and founder. "The opportunity to showcase Microcyn during a prestigious Columbia University eventa highly regarded institution which is on the cutting edge of new therapiesprovides us with an authoritative avenue to the entire spectrum of vascular clinicians including vascular surgeons, cardiologists, vascular nurses and podiatrists."
The conference is being held at the Marriott Marquis in New York City on May 10-11 with exhibition hours of 6:00 am until 5:00 pm daily.
About Oculus Innovative Sciences
Oculus Innovative Sciences is a commercial healthcare company that designs, produces and markets innovative, safe and effective healthcare products. Oculus is pioneering innovative solutions in multiple markets including dermatology, surgical, wound care, animal healthcare and others, and has commercialized products in the United States, Europe, India, China and Mexico and select Middle East countries. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. More information can be found at www.oculusis.com .
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the Company's commercial and technology progress and future financial performance. These forward-looking statements are identified by the use of words such as "showcase," "provides" and "exhibiting," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the annual report on Form 10-K for the year ended March 31, 2011. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements except as required by law.
Oculus and Microcyn Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.
CONTACT: Media and Investor Contact: Oculus Innovative Sciences, Inc. Dan McFadden Director of Public and Investor Relations (425) 753-2105 firstname.lastname@example.orgSource: Oculus Innovative Sciences, Inc. 2012 GlobeNewswire, Inc.